Emma Wang
Chief Development Officer & Chief technology officer YolTech Therapeutics
Dr. Emma Wang is the chief technology officer and co-founder at YolTech Therapeutics. Her focus is on advancing the non-viral delivery platform to support in vivo gene therapy development through research in novel lipid discovery, product development, process development, characterization as well as GMP manufacture. Prior to joining YolTech, Emma held research positions of growing responsibilities at Providence Therapeutics and Beam Therapeutics. Emma holds a Ph.D. in Chemistry as a member of Prof. Katharina Landfester’s group from Max Planck Institute for Polymer Research in Germany, a M.Eng and B.Eng in Chemical Engineering from McGill University in Canada.
Seminars
- Describing our expertise in metagenomics discovery and protein engineering with the help of High Throughput Evolution Platform for Discovery and Optimization of Novel Editors (HEPDONE) system.
- Introduce our proprietary lipid nanoparticle (LNP) mediated delivery systems targeting both liver and HSCs in the bone marrow
- Recent clinical trial readouts from our multiple ongoing in vivo genome editing programs in China will be discussed
NEW DATA
NEW COMPANY
